| Literature DB >> 22389220 |
Jeremy P Langrish1, Xi Li, Shengfeng Wang, Matthew M Y Lee, Gareth D Barnes, Mark R Miller, Flemming R Cassee, Nicholas A Boon, Ken Donaldson, Jing Li, Liming Li, Nicholas L Mills, David E Newby, Lixin Jiang.
Abstract
BACKGROUND: Air pollution exposure increases cardiovascular morbidity and mortality and is a major global public health concern.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22389220 PMCID: PMC3295351 DOI: 10.1289/ehp.1103898
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Baseline characteristics of subjects (n = 98) completing the study.
| Characteristic | Measure |
|---|---|
| Age (years) | 62 ± 7 |
| Male | 85 |
| Height (cm) | 169 ± 6 |
| Weight (kg) | 75 ± 10 |
| BMI (kg/m2) | 26 ± 3 |
| Risk factors | |
| Hypertension | 79 |
| Diabetes mellitus | 45 |
| Stroke | 15 |
| Peripheral vascular disease | 5 |
| Previous myocardial infarction | 68 |
| Previous PCI | 60 |
| Previous CABG | 38 |
| LV ejection fraction (%; | 62 ± 9 |
| Angina status | |
| CCS class I | 67 |
| CCS class II | 31 |
| Seattle angina score (maximum, 500) | 387 ± 34 |
| Clinical biochemistry | |
| Random glucose (mmol/L) | 5.5 ± 1.8 |
| Triglycerides (mmol/L) | 1.5 ± 0.7 |
| Cholesterol (mmol/L) | 3.9 ± 0.9 |
| HDL cholesterol (mmol/L) | 1.2 ± 0.3 |
| LDL cholesterol (mmol/L) | 2.0 ± 0.8 |
| Medication use | |
| Aspirin | 92 |
| Clopidogrel | 17 |
| Warfarin | 1 |
| ACE inhibitor or ARB | 54 |
| Beta blocker | 73 |
| Calcium channel blocker | 42 |
| Statin (fibrate, or ezetimibe) | 83 |
| Nitrate | 45 |
| Other antianginal | 5 |
| Diabetic medication | 42 |
| Traditional Chinese medicine | 19 |
| Abbreviations: ACE, angiotensin converting enzyme; ARB,
angiotensin II receptor blocker; BMI, body mass index; CABG, coronary
artery bypass graft; CCS, Canadian Cardiovascular Society; HDL, high
density lipoprotein; LDL, low density lipoprotein; LV, left ventricle;
PCI, percutaneous coronary intervention. Data are mean ± SD, or
| |
Figure 1Self-reported symptoms of well-being in the presence or absence of the face mask. *p < 0.05.
Personal ambient pollution exposures and background pollution levels on days defined according to mask use.
| Parameter | Mask | No mask | ||
|---|---|---|---|---|
| Personal PM2.5 exposure (μg/m3) | ||||
| Measured | 61 (20–88) | 89 (25–170) | ||
| Estimated | ~ 2 (0.6–2.6) | 89 (25–170) | ||
| Personal particle count (× 104 particles/cm3) | ||||
| Measured | 4.19 ± 1.29 | 4.39 ± 1.45 | ||
| Estimated | ~ 0.12 ± 0.04 | 4.39 ± 1.45 | ||
| Personal temperature (°C) | 17.3 ± 5.2 | 16.8 ± 5.8 | ||
| Personal relative humidity (%) | 30.4 ± 14.0 | 34.8 ± 18.2 | ||
| Personal peaks > 1 ppm (number) | ||||
| NO2 | None | None | ||
| SO2 | None | None | ||
| CO | 5 (2–7.5) | 4 (2–8) | ||
| Background exposure | ||||
| PM10 (μg/m3) | 92 (70–117) | 103 (83–180) | ||
| SO2 (ppb) | 38 (29–53) | 54 (32–77) | ||
| NO2 (ppb) | 36 (29–42) | 36 (32–47) | ||
| Abbreviations: CO, carbon monoxide; NO2, nitrogen dioxide; SO2, sulfur dioxide. Data are mean ± SD or median (interquartile range). Personal monitoring data were collected using portable monitoring equipment during the 2-hr walk. Background data were collected from permanent monitoring stations for the whole 24-hr period. Estimated PM exposure is calculated based on filter efficacy studies where 97% of fresh diesel exhaust PM were removed (Langrish et al. 2009). | ||||
Figure 2(A) Representative filter samples collected showing contribution by mass of the three size fractions averaged over 3 days. (B) Estimated contribution of each size fraction collected on filters by particle number. (C) Oxidative potential of the collected Beijing PM (1 mg/mL) using EPR to assess oxygen-centered free radical generation, compared with NIST diesel exhaust PM (10 μg/mL) and urban dust (1 mg/mL) and the prooxidant positive control (pyrogallol 100 μM) as described previously (Miller et al. 2009). Data are mean ± SD (n = 2–4).
Ambulatory blood pressure, heart rate variability during the 2-hr city center walk and the 24-hr study period, and myocardial ischemia measured as ischemic burden, in each individual territory and as a composite according to face mask use.
| Walk | 24 hr | |||||||
|---|---|---|---|---|---|---|---|---|
| Parameter | Mask | No mask | Mask | No mask | ||||
| Systolic blood pressure (mmHg) | 126.9 ± 15.9 | 128.1 ± 16.5 | 121.2 ± 11.9 | 120.8 ± 12.4 | ||||
| Diastolic blood pressure (mmHg) | 78.0 ± 9.3 | 79.5 ± 8.6 | 73.8 ± 7.2 | 74.0 ± 7.3 | ||||
| Mean arterial pressure (mmHg) | 93.3 ± 9.7* | 95.7 ± 10.0 | 89.8 ± 7.5 | 90.0 ± 7.9 | ||||
| Heart rate (bpm) | 81.5 ± 8.7 | 81.5 ± 10.1 | 77.6 ± 11.3 | 76.7 ± 11.1 | ||||
| LF power (msec2) | 133 (68–97) | 136 (52–227) | 81 (40–172) | 93 (46–208) | ||||
| HF power (msec2) | 54 (27–108)* | 40 (20–69) | 27 (11–77) | 31 (11–68) | ||||
| LFn (msec) | 58.4 (45.6–69.1)* | 62.9 (51.1–75.5) | 67.2 (55.5–78.0) | 71.1 (59.4–81.1) | ||||
| HFn (msec) | 23.5 (18.0–32.4)* | 20.5 (13.5–27.9) | 21.4 (15.0–31.6) | 20.9 (12.7–30.1) | ||||
| HF:LF ratio | 0.418 (0.258–0.712) | 0.328 (0.207–0.573) | 0.301 (0.190–0.554) | 0.306 (0.161–0.492) | ||||
| pNN50 (%) | 1.2 (0.2–2.8) | 0.7 (0.0–2.3) | 0.5 (0.0–3.1) | 0.6 (0.0–2.6) | ||||
| RMSSD (msec) | 16.7 (13.2–22.5)* | 14.8 (10.9–19.6) | 15.5 (11.0–22.6) | 14.4 (10.3–20.3) | ||||
| SDNN (msec) | 59.8 (46.4–79.1) | 60.1 (41.0–79.3) | 45.6 (30.8–70.4) | 48.2 (30.0–66.3) | ||||
| Ischemic burden (mV-sec) | ||||||||
| Inferior (II) territory | –66 (–118 to –26) | –52 (–149 to –21) | –641 (–767 to –504) | –615 (–820 to –473) | ||||
| Anterior (V2) territory | –66 (–142 to –16) | –50 (–124 to –13) | –597 (–859 to –435) | –632 (–905 to –489) | ||||
| Lateral (V5) territory | –37 (–104 to –8) | –43 (–85 to –18) | –604 (–811 to –429) | –586 (–790 to –412) | ||||
| Sum (II + V2 + V5) | –189 (–382 to –90) | –188 (–340 to –112) | –1,930 (–2,306 to –1,541) | –1,934 (–2,391 to –1,575) | ||||
| Abbreviations: LFn, low frequency–normalized; pNN50,
percentage of successive RR intervals that differ by > 50 msec; SDNN,
standard deviation of RR intervals. Data are mean ± SD, or median
(interquartile range). LFn and HFn are normalized units to account for
variation in the total power and very low-frequency components. LF and
SDNN reflect mainly sympathetic nervous stimulation; HF, pNN50, and
RMSSD reflect parasympathetic tone. * | ||||||||
Cardiac arrhythmias during 24-hr electrocardiographic monitoring periods among 98 coronary heart disease patients according to face mask use.
| No. patients | Median no. of events per patient (interquartile range) | |||||||
|---|---|---|---|---|---|---|---|---|
| Arrhythmia | Mask | No mask | Mask | No mask | ||||
| Dropped beat | 2 | 2 | 1 (1–1) | 1 (1–1) | ||||
| VT | 1 | 2 | 2 (2–2) | 1 (1–1) | ||||
| Salvo | 1 | 2 | 4 (4–4) | 2 (1–3) | ||||
| Bigeminy | 15 | 18 | 4 (1–33) | 6 (2–36) | ||||
| Triplet | 1 | 0 | 11 (11–11) | 0 (0–0) | ||||
| Couplet | 9 | 4 | 2 (1–5) | 2 (1–10) | ||||
| Bradycardia | 20 | 19 | 52 (3–275) | 89 (9–347) | ||||
| SVT | 2 | 5 | 1 (1–1) | 1 (1–1) | ||||
| Trigeminy | 3 | 4 | 12 (6–134) | 10 (6–230) | ||||
| Premature aberrant | 79 | 77 | 17 (3–122) | 22 (3–181) | ||||
| Isolated aberrant | 52 | 54 | 3 (1–16) | 5 (1–25) | ||||
| Premature normal | 81 | 84 | 12 (3–56) | 12 (3–42) | ||||
| Abbreviations: SVT, supraventricular tachycardia; VT,
ventricular tachycardia. Bradycardia defined as heart rate < 50 bpm.
| ||||||||